

AUG 30 2007

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence and all accompanying papers, if any, are being sent via facsimile to the United States Patent and Trademark Office at facsimile number 571-273-8300 on the date indicated below.

Robert P. Udall      8/30/2007  
Robert P. Udall      Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appl. No.** : 10/646,904  
**Applicant** : Herbert Irschik et al.  
**Filed** : August 22, 2003  
**Title** : Use of Disorazoles and Their Derivatives for the Treatment of Benign And Malignant Oncoses  
**Examiner** : Sabiha Naim Qazi  
**Art Unit** : 1616  
**AttyDocket No.** : 103832-510-NP

Commissioner for Patents

P. O. Box 1450  
Alexandria, VA 22313-1450.**INFORMATION DISCLOSURE STATEMENT**

Dear Sir or Madam:

In accordance with the duty of disclosure under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants would like to direct the Examiner's attention to the following Russian Publication which is listed on Form PTO/SB/08B and below as item 1 is attached hereto as **Exhibits 1**. An English translation of the Russian Publication is hereto attached as **Exhibit 2**.

1. Belikov, V. G., Pharmaceutical Chemistry, 2<sup>nd</sup> edition, Moscow "Vysshaya Shkola" 1993, pp. 42-47 (**Exhibit 1**).


This Information Disclosure Statement ("IDS") is submitted concurrently with an RCE request and a Notice of Appeal. Therefore, pursuant to 37 CFR § 1.97 (b)(3), there is no fee for filing

Page 1 of 2

LIBNY/4630596.1

this Information Disclosure Statement. However, the commissioner is authorized to charge any required fees and any additional fees, or credit any overpayment to Goodwin Procter LLP Deposit Account No. 06-0923.

Respectfully submitted for Applicants,



---

Robert Udal (Reg. No. 56,608)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
(212) 813-8840

AUG 30 2007

PTO/SB/08B (04-07)

Approved for use through 08/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete If Known</b>			
		Application Number	10/646,904		
		Filing Date	August 22, 2003		
		First Named Inventor	Herbert Irschik et al.		
		Art Unit	1616		
		Examiner Name	Sabiha Naim Qazi		
Sheet	1	of	1	Attorney Docket Number	103832-510-NP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		V. G. BELIKOV, Pharmaceutical Chemistry, 2nd edition, Moscow "Vysshaya Shkola" 1993, pp. 42-47.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.